- €52.67bn
- €60.26bn
- €21.16bn
- 73
- 32
- 40
- 43
Annual income statement for Merck KGaA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 17,534 | 19,687 | 22,232 | 20,993 | 21,156 |
Cost of Revenue | |||||
Gross Profit | 10,752 | 12,362 | 13,819 | 12,623 | 12,577 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 14,549 | 15,508 | 17,758 | 17,384 | 17,511 |
Operating Profit | 2,985 | 4,179 | 4,474 | 3,609 | 3,645 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2,630 | 3,924 | 4,287 | 3,484 | 3,536 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,993 | 3,065 | 3,339 | 2,834 | 2,785 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 1,986 | 3,055 | 3,325 | 2,824 | 2,776 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,987 | 3,055 | 3,326 | 2,824 | 2,777 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.72 | 7.36 | 8.77 | 7.58 | 7.72 |
Dividends per Share |